X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs UNICHEM LAB - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS UNICHEM LAB NOVARTIS/
UNICHEM LAB
 
P/E (TTM) x 416.3 225.1 184.9% View Chart
P/BV x 29.4 0.6 4,854.4% View Chart
Dividend Yield % 1.6 2.3 68.0%  

Financials

 NOVARTIS   UNICHEM LAB
EQUITY SHARE DATA
    NOVARTIS
Mar-18
UNICHEM LAB
Mar-19
NOVARTIS/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs758292 259.6%   
Low Rs579182 318.1%   
Sales per share (Unadj.) Rs228.4167.7 136.2%  
Earnings per share (Unadj.) Rs31.7-3.6 -874.1%  
Cash flow per share (Unadj.) Rs32.85.9 551.4%  
Dividends per share (Unadj.) Rs10.004.00 250.0%  
Dividend yield (eoy) %1.51.7 88.6%  
Book value per share (Unadj.) Rs297.1372.3 79.8%  
Shares outstanding (eoy) m24.6970.38 35.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.91.4 207.1%   
Avg P/E ratio x21.1-65.3 -32.3%  
P/CF ratio (eoy) x20.439.9 51.2%  
Price / Book Value ratio x2.20.6 353.4%  
Dividend payout %31.5-110.2 -28.6%   
Avg Mkt Cap Rs m16,50516,680 99.0%   
No. of employees `0000.72.6 25.7%   
Total wages/salary Rs m1,4452,393 60.4%   
Avg. sales/employee Rs Th8,441.34,535.2 186.1%   
Avg. wages/employee Rs Th2,163.6919.8 235.2%   
Avg. net profit/employee Rs Th1,173.1-98.2 -1,194.5%   
INCOME DATA
Net Sales Rs m5,63911,801 47.8%  
Other income Rs m1,718984 174.6%   
Total revenues Rs m7,35712,785 57.5%   
Gross profit Rs m-63-835 7.5%  
Depreciation Rs m25674 3.8%   
Interest Rs m5575 73.5%   
Profit before tax Rs m1,575-600 -262.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792-343 -230.5%   
Profit after tax Rs m784-256 -306.7%  
Gross profit margin %-1.1-7.1 15.7%  
Effective tax rate %50.357.3 87.7%   
Net profit margin %13.9-2.2 -641.8%  
BALANCE SHEET DATA
Current assets Rs m9,52220,384 46.7%   
Current liabilities Rs m3,2965,029 65.5%   
Net working cap to sales %110.4130.1 84.8%  
Current ratio x2.94.1 71.3%  
Inventory Days Days37105 35.0%  
Debtors Days Days28135 21.1%  
Net fixed assets Rs m469,023 0.5%   
Share capital Rs m123141 87.6%   
"Free" reserves Rs m7,21326,058 27.7%   
Net worth Rs m7,33626,199 28.0%   
Long term debt Rs m00-   
Total assets Rs m11,10531,496 35.3%  
Interest coverage x29.5-7.0 -422.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.4 135.5%   
Return on assets %7.6-0.6 -1,319.4%  
Return on equity %10.7-1.0 -1,095.1%  
Return on capital %22.2-2.0 -1,111.6%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m618,188 0.7%   
Fx outflow Rs m3,630596 609.1%   
Net fx Rs m-3,5707,592 -47.0%   
CASH FLOW
From Operations Rs m1,610-3,278 -49.1%  
From Investments Rs m687-2,860 -24.0%  
From Financial Activity Rs m-2,677-24 11,059.9%  
Net Cashflow Rs m-380-4,690 8.1%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 15.1 13.2%  
FIIs % 1.6 3.0 53.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 31.7 67.8%  
Shareholders   41,647 20,176 206.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend; Sensex Ends 48 Points Lower(Closing)

After opening the day on a flat note, share markets in India witnessed selling pressure during closing hours and ended marginally lower.

Related Views on News

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 23, 2019 03:35 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS